Iterum Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
March 12, 2020 06:45 ET
|
Iterum Therapeutics plc
--Topline data from cUTI and uUTI pivotal trials on track to report around the end of Q1----NDAs anticipated to file with the FDA in mid-2020-- DUBLIN, Ireland and CHICAGO, March 12, 2020 ...
Iterum Therapeutics Reports Second Quarter 2019 Financial Results
August 14, 2019 07:00 ET
|
Iterum Therapeutics plc
--Phase 3 Topline Data anticipated in the fourth quarter-- -- NDA filings expected in first quarter of 2020-- DUBLIN, Ireland and CHICAGO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc...
Iterum Therapeutics Presents Data Highlighting Antibiotic Sulopenem at IDWeek 2018
October 05, 2018 08:00 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant...
Iterum to Present at Cantor Fitzgerald Global Healthcare Conference
September 25, 2018 16:05 ET
|
Iterum Therapeutics plc
DUBLIN and CHICAGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens,...
Iterum Initiates SURE 2 and SURE 3 Phase 3 Clinical Trials of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections
September 18, 2018 08:00 ET
|
Iterum Therapeutics plc
Remaining two of three planned Phase 3 pivotal trials now underway for Iterum’s lead antibiotic product candidate sulopenem Potential to be first and only oral and IV penem antibiotic available...
Iterum Reports Second Quarter 2018 Financial Results and Recent Highlights
August 14, 2018 07:30 ET
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company developing anti-infectives against multi-drug resistant...
Iterum Initiates SURE 1, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
August 09, 2018 16:05 ET
|
Iterum Therapeutics plc
First of three planned Phase 3 pivotal trials now underway for Iterum’s oral antibiotic Oral sulopenem, if approved, could be the first antibiotic for uncomplicated urinary tract infections in over...